|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 2:** Adverse events in sunitinib-treated patients classified by age | | | | | | |
| **Adverse Event** | **Variable** | | | | **p values** | |
| **Age < 75 years (n=38)** | | **Age ≥ 75 years (n=9)** | |
|  | **All grade** | **≥Grade 3** | **All grade** | **≥ Grade 3** | **All grade** | **≥ Grade 3** |
| **Symptoms, n(%)** |  |  |  |  |  |  |
| Nausea | 20(53) | 0(0) | 3(33) | 0(0) | 0.2977 | - |
| Fever | 16(42) | 0(0) | 3(33) | 0(0) | 0.6297 | - |
| Fatigue | 15(39) | 0(0) | 3(33) | 0(0) | 0.7333 | - |
| Anorexia | 15(39) | 2(5) | 3(33) | 2(22) | 0.7333 | 0.1011 |
| Hand-foot syndrome | 14(37) | 3(8) | 4(44) | 2(22) | 0.6731 | 0.216 |
| Hypertension (de novo) | 14(37) | 2(5) | 4(44) | 0(0) | 0.6731 | 0.4818 |
| Stomatitis | 13(34) | 2(5) | 3(33) | 1(11) | 0.9602 | 0.5187 |
| Diarrhea | 10(26) | 0(0) | 3(33) | 1(11) | 0.6722 | 0.0378 |
| Peripheral edema | 6(16) | 0(0) | 2(22) | 0(0) | 0.6443 | - |
| Gastrointestinal hemorrhage | 5(13) | 1(3) | 2(22) | 0(0) | 0.4922 | 0.6228 |
| **Abnormal laboratory data, n(%)** |  |  |  |  |  |  |
| AST increased | 31(82) | 2(5) | 8(89) | 0(0) | 0.5998 | 0.4818 |
| ALP increased | 25(66) | 1(3) | 6(67) | 0(0) | 0.9602 | 0.6228 |
| Platelet count decreased | 24(63) | 14(37) | 7(78) | 3(33) | 0.4053 | 0.8438 |
| ALT increased | 22(58) | 3(8) | 6(67) | 0(0) | 0.6297 | 0.3837 |
| Hypothyroidism\* | 21(55) | 2(5) | 2(22) | 0(0) | 0.0746 | 0.4818 |
| Creatinine increased | 20(53) | 1(3) | 4(44) | 0(0) | 0.8349 | 0.6382 |
| Neutrophil count decreased | 19(50) | 10(26) | 6(67) | 3(33) | 0.3676 | 0.6722 |
| Leukocyte count decreased | 17(45) | 11(29) | 6(67) | 3(33) | 0.2367 | 0.7959 |
| Hyponatremia | 17(45) | 4(11) | 4(44) | 0(0) | 0.9354 | 0.3019 |
| Blood urea nitrogen increased | 16(42) | 1(3) | 5(56) | 0(0) | 0.506 | 0.618 |
| Hypocalcemia | 15(39) | 1(3) | 4(44) | 0(0) | 0.7847 | 0.6228 |
| Hypophosphatemia | 14(37) | 4(11) | 2(22) | 0(0) | 0.4053 | 0.3089 |
| Hyperkalemia | 13(34) | 0(0) | 3(33) | 0(0) | 0.9602 | - |
| Gamma-GTP increased | 12(32) | 2(5) | 2(22) | 0(0) | 0.581 | 0.4818 |
| Serum amylase increased | 12(32) | 3(8) | 2(22) | 0(0) | 0.581 | 0.3837 |
| Hyperuricemia | 12(32) | 0(0) | 2(22) | 0(0) | 0.7132 | - |
| Hypercalcemia | 9(24) | 0(0) | 1(11) | 0(0) | 0.4073 | - |
| Hypokalemia | 8(21) | 1(3) | 1(11) | 0(0) | 0.4955 | 0.6228 |
| lipase Increased | 6(16) | 3(8) | 2(22) | 1(11) | 0.6443 | 0.7559 |
| Total bilirubin increased | 6(16) | 0(0) | 2(22) | 0(0) | 0.6443 | - |
| Graded according to CTCAEv3.0, and occurring in at least 20% of patients, or including patients with grade 3 or 4 adverse events.  \*: Hypothyroidism consists of thyroid hormone decreased and thyroid-stimulating hormone increased, and most patients received medication before symptom appearance.  **Abbreviations:** AST: aspartate aminotransferase; ALP: alkaline phosphatase; ALT: alanine aminotransferase; GTP: glutamyl transpeptidase | | | | | | |
|
|
|